AstraZeneca: Lymphoma, Non-Hodgkin trials
The registry lists 19 Lymphoma, Non-Hodgkin studies with AstraZeneca as lead sponsor. 3 are open to participants now and 8 have results posted.
Phase 1 12Phase 2 10Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT07123454Phase 1/2
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruitingNCT06526793Phase 2
- AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/2
- A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin LymphomaTerminatedNCT05205161Phase 1Results posted
- Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompletedNCT02328014Phase 1/2Results posted
- Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell LymphomasCompletedNCT02271945Phase 1/2Results posted
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02180711Phase 1/2Results posted
- A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01466153Phase 2Results posted
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01453205Phase 2Results posted
- Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)CompletedNCT01030536Phase 1/2Results posted
- CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaCompletedNCT00659425Phase 1Results posted
- Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From CerdulatinibNo longer availableNCT04757259
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnNCT04021082Phase 2/3
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- A Phase I Study to Evaluate Safety, Tolerability in Adults With LymphomaWithdrawnNCT00538096Phase 1
- Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877TerminatedNCT00471367Phase 1
- BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00126646Phase 1